SCHEMBL798345

SCHEMBL798345

CON1C(=O)c2ccccc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.52
VDR P11473 1/20 0.48
ALDH1A1 P00352 6/20 0.48
MAPT P10636 5/20 0.48
KDM4E B2RXH2 4/20 0.48
HPGD P15428 4/20 0.48
KMT2A Q03164 4/20 0.48
RECQL P46063 1/20 0.47
CASP3 P42574 1/20 0.46
CYP1A2 P05177 3/20 0.46
LMNA P02545 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP2C9 P11712 2/20 0.46
MAP2K7 O14733 1/20 0.46
GMNN O75496 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30219494 1.00 GAA (0.52) GAAVDRALDH1A1MAPTKDM4E
SCHEMBL13495401 0.82 MAOA (0.43) GAAVDRALDH1A1MAPTKDM4E
SCHEMBL10040988 0.81 TDP1 (0.60) GAAALDH1A1MAPTKDM4EHPGD
SCHEMBL12540917 0.80 NPC1 (0.42) ALDH1A1MAPTKDM4EHPGDKMT2A
SCHEMBL262472 0.79 GAA (0.56) GAAVDRALDH1A1MAPTKDM4E
SCHEMBL20768726 0.79 GAA (0.56) GAAVDRALDH1A1MAPTKDM4E
SCHEMBL13495404 0.79 MAOA (0.41) GAAVDRALDH1A1MAPTKDM4E
SCHEMBL24168448 0.78 MEN1 (0.59) GAAVDRALDH1A1MAPTKDM4E
SCHEMBL13495402 0.78 CYP2D6 (0.50) GAAALDH1A1KDM4EHPGDKMT2A
SCHEMBL13495393 0.78 DPP4 (0.47) ALDH1A1KMT2APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115672395-B Catalyst system and method for preparing 2-nitro-4-methylsulfonyl benzoic acid by catalytic oxidation 宁夏伟创药业有限公司 2024-06-14 CN claimed
CN-115672395-A Catalyst system and method for preparing 2-nitro-4-methylsulfonylbenzoic acid by catalytic oxidation 宁夏伟创药业有限公司 2023-02-03 CN claimed
CN-112410965-B Fluorescent flame-retardant arc-proof yarn, preparation method thereof and fabric 常熟市宝沣特种纤维有限公司 2021-12-07 CN claimed
CN-112410965-A Fluorescent flame-retardant arc-proof yarn, preparation method thereof and fabric 常熟市宝沣特种纤维有限公司 2021-02-26 CN claimed
EP-1028124-B2 Improved deprotection method for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS INC (US) 2016-01-27 EP claimed
EP-1028124-B1 Improved deprotection method for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS INC (US) 2007-10-31 EP claimed
US-20050137391-A1 Process for the synthesis of oligomeric compounds IONIS PHARMACEUTICALS, INC. 2005-06-23 US claimed
US-20030088088-A1 Process for the synthesis of oligomeric compounds IONIS PHARMACEUTICALS, INC. 2003-05-08 US claimed
EP-1028124-A2 Improved process for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS, INC. (US) 2000-08-16 EP claimed
EP-4562002-A1 SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER Nodus Oncology Limited (GB) 2025-06-04 EP disclosed
CN-115672395-B Catalyst system and method for preparing 2-nitro-4-methylsulfonyl benzoic acid by catalytic oxidation 宁夏伟创药业有限公司 2024-06-14 CN disclosed
CN-115672395-B Catalyst system and method for preparing 2-nitro-4-methylsulfonyl benzoic acid by catalytic oxidation 宁夏伟创药业有限公司 2024-06-14 CN disclosed
CN-117777005-A Synthesis method of N-aryl phthalimide compound 清源创新实验室 2024-03-29 CN disclosed
WO-2024023330-A1 SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER NODUS ONCOLOGY LIMITED (GB) 2024-02-01 WO disclosed
EP-1028124-A2 Improved process for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS, INC. (US) 2000-08-16 EP disclosed
EP-0927717-A1 PROCESS FOR PRODUCING HYDROPEROXIDES Mitsui Chemicals, Inc. (JP) 1999-07-07 EP disclosed
US-5789434-A ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION BAYER CORPORATION (US) 1998-08-04 US disclosed
US-5001115-A Prodrugs of biologically active hydroxyaromatic compounds UNIVERSITY OF FLORIDA (US) 1991-03-19 US disclosed
EP-0046064-A1 Non-silver image-forming composition EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1982-02-17 EP disclosed
US-4308341-A PROVIDING ISOINDOZE DYES BY REACTION OF COBALT AMINE LIGANDS AND AROMATIC DIALDEHYDES EASTMAN KODAK COMPANY (US) 1981-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137391-A1 Process for the synthesis of oligomeric compounds PFAS, DIS3, EXOSC4 GAA 2656/4885VDR 4540/4885ALDH1A1 3004/4885
US-20030088088-A1 Process for the synthesis of oligomeric compounds PFAS, DIS3, EXOSC4 GAA 2656/4885VDR 4540/4885ALDH1A1 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.